OSTX - NYSE
OS Therapies Incorporated
$1.42
-2.1%OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
At a Glance
Live Snapshotostx
Selling, General and Administrative Expenses
Last Annual Value
3.97M
3-Year CAGR
38%
5-Year CAGR
449%
10-Year CAGR
134%
OS Therapies Incorporated Competitors Analysis of Selling, General and Administrative Expenses
| Company | Selling, General and Administrative Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
 OS Therapies Incorporated NYSE:OSTX | 3.97M | 52.5% | 21.5% | N/A | |
 CervoMed Inc. NASDAQ:CRVO | 9.17M | 12.0% | 4.2% | 0.6% | |
 MediciNova, Inc. NASDAQ:MNOV | 6.16M | 5.5% | 1.5% | -1.8% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 20.72M | -12.2% | -6.2% | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 16.24M | -0.9% | -1.3% | 23.5% | |
 Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO | 8.10M | 138.1% | 270.3% | N/A | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 15.85M | -5.3% | 1.4% | N/A | |
 Spruce Biosciences, Inc. NASDAQ:SPRB | 16.99M | 10.3% | 8.4% | N/A | |
 Coeptis Therapeutics, Inc. NASDAQ:COEP | 1.25M | -55.1% | -38.4% | N/A | |
 NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 13.06M | -2.8% | -29.5% | N/A | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 39938.23B | 11340.3% | 1890.9% | 323.4% |
OS Therapies Incorporated Fair Value Envelope
Related Guides
Continue your OSTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.